Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta‐Analysis and Systematic Review

To evaluate the cardiovascular (CV) effects of acetylcholinesterase inhibitors (AChEIs) in individuals with dementia

[1]  R. Stewart,et al.  Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis , 2018, Age and ageing.

[2]  Claudio Luchini,et al.  Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale , 2017 .

[3]  I. Boutron,et al.  Exclusion of patients with concomitant chronic conditions in ongoing randomised controlled trials targeting 10 common chronic conditions and registered at ClinicalTrials.gov: a systematic review of registration details , 2016, BMJ Open.

[4]  Yi-Ting Lin,et al.  Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementia , 2016, Scientific Reports.

[5]  G. Sergi,et al.  Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  Winston Yu-Chen Chen,et al.  Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada , 2015, PloS one.

[7]  Xi He,et al.  Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases , 2015, British journal of pharmacology.

[8]  Asymptomatic Bradycardia Due to Rivastigmine in an Elderly Adult with Lewy Body Dementia , 2015, Journal of the American Geriatrics Society.

[9]  Yi-Ting Lin,et al.  Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia , 2015, Scientific Reports.

[10]  C. van Walraven,et al.  The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada , 2015, BMC Neurology.

[11]  P. Soysal,et al.  Which Rivastigmine Formula is Better for Heart in Elderly Patients With Alzheimer’s Disease , 2014, American journal of Alzheimer's disease and other dementias.

[12]  T. Someya,et al.  Cardiovascular pharmacodynamics of donepezil hydrochloride on the PR and QT intervals in patients with dementia , 2014, Human psychopharmacology.

[13]  M. Riepe.  High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease. , 2014, The Journal of clinical psychiatry.

[14]  L. Saso,et al.  Antioxidant activity of galantamine and some of its derivatives. , 2013, Current medicinal chemistry.

[15]  B. Winblad,et al.  The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. , 2013, European heart journal.

[16]  R. Marcos,et al.  The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies. , 2013 .

[17]  Zhenxin Zhang,et al.  Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study , 2012, Neuropsychiatric disease and treatment.

[18]  Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands. , 2012, The American journal of geriatric pharmacotherapy.

[19]  A. Diedrich,et al.  Influences of Donepezil on Cardiovascular System—Possible Therapeutic Benefits for Heart Failure—DOnepezil Cardiac TEst Registry (DOCTER) Study , 2012, Journal of cardiovascular pharmacology.

[20]  R. Doody,et al.  Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine , 2012, Dementia and Geriatric Cognitive Disorders.

[21]  Which Cholinesterase Inhibitor is the Safest for the Heart in Elderly Patients With Alzheimer’s Disease? , 2012, American journal of Alzheimer's disease and other dementias.

[22]  A. Işık,et al.  Cardiac safety of donepezil in elderly patients with Alzheimer disease. , 2012, Internal medicine.

[23]  T. Mets,et al.  Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: A study in a real life population , 2011, Geriatrics & gerontology international.

[24]  M. Farlow,et al.  Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease , 2011, BMC neurology.

[25]  A. Işık,et al.  Late onset Alzheimer’s disease in older people , 2010, Clinical interventions in aging.

[26]  A. Işık,et al.  Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease. , 2010, The American journal of geriatric pharmacotherapy.

[27]  A. Diedrich,et al.  The Effect of Donepezil Treatment on Cardiovascular Mortality , 2010, Clinical pharmacology and therapeutics.

[28]  P. Tariot,et al.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. , 2010, Clinical therapeutics.

[29]  J. Claassen,et al.  GALANTAMINE DOES NOT CAUSE AGGRAVATED ORTHOSTATIC HYPOTENSION IN PEOPLE WITH ALZHEIMER'S DISEASE , 2010, Journal of the American Geriatrics Society.

[30]  E. Lawler,et al.  Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System , 2009, Journal of the American Geriatrics Society.

[31]  A. Laupacis,et al.  Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study , 2009, PLoS medicine.

[32]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[33]  S. Normand,et al.  Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. , 2009, Archives of internal medicine.

[34]  J. Olin,et al.  Switching from Donepezil Tablets to Rivastigmine Transdermal Patch in Alzheimer's Disease , 2009, American journal of Alzheimer's disease and other dementias.

[35]  P. Scheltens,et al.  Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study , 2008, Current medical research and opinion.

[36]  C. Sadowsky,et al.  Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. , 2008, Primary care companion to the Journal of clinical psychiatry.

[37]  G. Figiel,et al.  Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study. , 2008, Primary care companion to the Journal of clinical psychiatry.

[38]  R. Doody,et al.  Safety and Tolerability of Donepezil at Doses up to 20 mg/day , 2008, Drugs & aging.

[39]  H. Sauer,et al.  Influence of Galantamine on Vasomotor Reactivity in Alzheimer’s Disease and Vascular Dementia Due to Cerebral Microangiopathy , 2007, Stroke.

[40]  J. Lindesay,et al.  Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists' practice. , 2007, Age and ageing.

[41]  I. Kloszewska,et al.  Cholinesterase inhibitors in the "real world" setting: rivastigmine versus donepezil tolerability and effectiveness study , 2006 .

[42]  S. Garrigue,et al.  Cardiovascular Effects and Risk of Syncope Related to Donepezil in Patients with Alzheimer’s Disease , 2006, CNS drugs.

[43]  Y. Kakinuma,et al.  Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non‐hypoxic induction of HIF‐1α , 2005, FEBS letters.

[44]  M. Luca,et al.  Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients , 2005, Journal of the Neurological Sciences.

[45]  Y. Masuda.  Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease--from basic research to bedside. , 2004, Current Alzheimer research.

[46]  K. Shulman,et al.  Representation of patients with dementia in clinical trials of donepezil. , 2004, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[47]  A. Murray,et al.  Cardiovascular Effects of Donepezil in Patients with Dementia , 2003, Dementia and Geriatric Cognitive Disorders.

[48]  Y. Masuda,et al.  Acetylcholinesterase Inhibitor (Donepezil Hydrochloride) Reduces Heart Rate Variability , 2003, Journal of cardiovascular pharmacology.

[49]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[50]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[51]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.